Related Experiment Video
Updated: Jun 26, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Edaravone derivatives containing NO-donor functions
Konstantin Chegaev1, Clara Cena, Marta Giorgis
1Dipartimento di Scienza e Tecnologia del Farmaco, Universita degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy.
Abstract:
A new series of polyvalent drugs obtained by joining edaravone with NO-donor moieties is described. All compounds display high antioxidant power together with NO-dependent vasodilator properties. The analysis of a number of molecular descriptors shows that the antioxidant activity, which is tightly linked to the presence of the edaravone substructure, is principally modulated by lipophilicity. These products are potentially useful in the treatment of cardiovascular disorders in which EDRF deficiency and ROS excess are involved.
Related Concept Videos
Hemodialysis I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Antiviral Nucleoside Inhibitors
